CJC-1295 exists in two forms that share a backbone and almost nothing else: the DAC version, which binds albumin and carries the only human trial data, and the no-DAC version sold as Mod GRF 1-29. This guide separates them by source — the doses the trials used, the measured half-lives, and what a test report can and cannot establish. Educational use only, not medical advice.
Standard Access: This compound's three paid filesAll-Access Lifetime: all 55 guides + every printableEducational content only
Foundational Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
CJC-1295 at a glance
What it is
A synthetic analogue of GHRH(1-29), the shortest fully active fragment of growth-hormone-releasing hormone. Two forms are sold under one name: with DAC (Drug Affinity Complex) and without DAC, the latter being the same molecule marketed as Mod GRF 1-29 or CJC-1295 no-DAC.
What the DAC actually is
Not a coating or a carrier. CJC-1295 was identified as a tetra-substituted hGRF(1-29) carrying an N-epsilon-3-maleimidopropionamide derivative of lysine at the C-terminus (PMID 15817669). That maleimide reacts with the free thiol on cysteine-34 of circulating serum albumin, so the peptide becomes covalently attached to albumin in the bloodstream.
The dose with data behind it
DAC form — 30, 60 and 90 mcg/kg as single subcutaneous injections across two trials (PMID 16352683, PMID 17018654) — roughly 2,100, 4,200 and 6,300 mcg for a 70 kg adult. The weekly amounts quoted in community sources for the DAC form sit below the smallest single dose either trial administered.
Human dose actually studied (no DAC)
None. No human efficacy or pharmacokinetic trial of the no-DAC peptide is indexed in PubMed. Every human number on this page belongs to the DAC form.
Plasma half-life
DAC form: 5.8-8.1 days (PMID 16352683). No-DAC form: no published human measurement — see below. This is a measurement in healthy adults, not an estimate — and it is a property of the albumin conjugate, not of the GHRH backbone.
The no-DAC '30 minutes'
Not a measurement of this peptide. It is inherited from GHRH(1-29) chemistry: unmodified GRF(1-29)NH2 is cleaved by dipeptidyl peptidase IV to the inactive fragment GRF(3-29)NH2, and the substitutions in the Mod GRF backbone are the ones designed to resist that cleavage (PMID 8583376). See the half-life section for what that does and does not license.
Mechanism
GHRH-receptor agonism at the pituitary somatotroph, raising GH and downstream IGF-1. Notably, pulsatility survives it: after a single injection, GH secretion increased with pulsatility preserved (PMID 17018654).
Registered trials
One study lists CJC-1295 as an intervention on ClinicalTrials.gov — NCT00267527, in HIV patients with visceral obesity — and its status is TERMINATED. There is no approved product in either form.
Regulatory status
Not FDA-approved in either form; prohibited in sport under the WADA list. Research and educational use only.
Educational reference. This page does not publish dose ranges or reconstitution arithmetic.
What it is / mechanism
CJC-1295 acts at the growth-hormone-releasing hormone receptor on pituitary somatotrophs, the same receptor the endogenous hormone uses. Agonism there raises growth hormone output, and the sustained rise in GH drives hepatic IGF-1 production, which is the downstream marker both human trials tracked. Nothing about the mechanism is exotic; the whole engineering story is about how long the molecule survives to keep doing it.
That story starts with a specific enzymatic vulnerability. Native GHRH(1-29) is cleaved rapidly in plasma by dipeptidyl peptidase IV, which removes the first two residues and leaves GRF(3-29)NH2 — a fragment reported as the major metabolite and as inactive (PMID 8583376). The same paper showed that a substituted analogue, [desNH2Tyr1, D-Ala2, Ala15]-GRF(1-29)NH2, was resistant to that plasma cleavage and dramatically more stable. The D-alanine at position 2 is the substitution that matters most: DPP-IV cleaves after the second residue, and a D-amino acid there is not a substrate it recognises. The tetra-substituted backbone shared by CJC-1295 and Mod GRF 1-29 exists for that reason.
The DAC is a second, separate piece of engineering layered on top. In the paper that identified the compound, three maleimido derivatives of hGRF(1-29) were synthesised and bioconjugated to human serum albumin; the best of them, designated CJC-1295, was a tetra-substituted hGRF(1-29) with an N-epsilon-3-maleimidopropionamide derivative of lysine added at the C-terminus (PMID 15817669). Maleimides react selectively with free thiols, and the one free thiol available in circulation at any useful concentration is cysteine-34 of serum albumin. So the injected peptide finds albumin and forms a covalent bond with it. In rats, plasma levels persisted beyond 72 hours, and a western blot of plasma from an injected animal showed the CJC-1295 immunoreactive species sitting on the band corresponding to serum albumin, appearing after 15 minutes and remaining beyond 24 hours.
That is the whole difference between the two products sold under this name. Both share a DPP-IV-resistant GHRH(1-29) backbone. Only one of them carries the chemistry that attaches it to a protein with a multi-week circulating lifetime. Treating them as the same compound at different strengths misdescribes what was built.
One mechanistic result deserves its own line, because it is counter-intuitive and it was measured rather than assumed. A standing objection to any long-acting GHRH analogue is that continuous receptor stimulation should flatten the natural GH rhythm, and pulsatile GH secretion is considered important for many of the hormone's physiological effects. Ionescu and Frohman tested it directly: healthy men aged 20-40 were sampled every 20 minutes across an overnight 12-hour window, before and one week after a single injection of 60 or 90 mcg/kg. GH secretion was increased with pulsatility preserved (PMID 17018654). Whatever else is uncertain here, that specific worry was checked in humans and did not materialise at those doses.
Researched effects
The honest summary is that the human evidence for CJC-1295 is three Phase 1-scale pharmacology studies in healthy volunteers, all on the DAC form — no efficacy trial, no long-term study, and no completed clinical programme.
The pharmacokinetic study (PMID 16352683) ran two randomised, placebo-controlled, double-blind ascending-dose trials of 28 and 49 days in healthy subjects aged 21-61. CJC-1295 or placebo was given subcutaneously as ascending single doses in the first trial and as two or three weekly or biweekly doses in the second. After a single injection, mean plasma GH rose 2- to 10-fold for six days or more, and mean plasma IGF-1 rose 1.5- to 3-fold for nine to eleven days. After multiple doses, mean IGF-1 remained above baseline for up to 28 days. The estimated half-life was 5.8-8.1 days. No serious adverse reactions were reported, and the authors singled out doses of 30 or 60 mcg/kg as safe and relatively well tolerated.
The pulsatility study (PMID 17018654) is the second human dataset. Single injections of 60 or 90 mcg/kg, overnight 20-minute sampling before and one week after, GH increased with pulsatility preserved.
A third study (PMID 19386527, 2009) looked for biomarkers rather than for an effect: it examined serum protein profile changes after GH/IGF-1 axis activation by CJC-1295 in normal adult subjects, motivated by the fact that the existing markers of GH activity — IGF-1, IGFBP-3 and collagen peptides — vary substantially across the population and are not reliably predictive of GH therapy's physiological effects or of GH abuse by athletes. It is worth knowing this study exists, and worth being clear about what it is: a biomarker-discovery study in which the compound is the tool, not the subject.
Two things follow that the market rarely states together. First, both trials measured hormone concentrations in healthy volunteers — GH and IGF-1 levels, not body composition, not strength, not recovery, not sleep. An IGF-1 rise is a pharmacodynamic response, and reading it as a clinical outcome is an inference the trials did not make. Second, the development programme that generated these data did not continue to an approved product. The one registered study listing CJC-1295 as an intervention, NCT00267527 in HIV patients with visceral obesity, is recorded as terminated, and no CJC-1295 product has been approved in any jurisdiction.
For the no-DAC form the evidence section is shorter, because it is empty. PubMed indexes no human efficacy or pharmacokinetic trial of the tetra-substituted peptide without the DAC. Every human figure quoted for CJC-1295 anywhere — the half-life, the GH multiples, the IGF-1 duration, the tolerability — was generated using the albumin-binding version. When those numbers appear on a page about the no-DAC product, they have been moved across a molecular boundary that the chemistry does not permit.
Evidence & regulatory status
Human pharmacokinetics (DAC form): PMID 16352683 — randomised, double-blind, placebo-controlled ascending-dose trials in healthy adults; half-life 5.8-8.1 days; GH 2-10x for 6+ days; IGF-1 1.5-3x for 9-11 days; IGF-1 above baseline up to 28 days after multiple doses; 30 and 60 mcg/kg identified as well tolerated.
Human GH pulsatility (DAC form): PMID 17018654 — single 60 or 90 mcg/kg injection in healthy men, 12-hour overnight sampling at 20-minute intervals before and one week after; GH secretion increased with pulsatility preserved.
Third human dataset (DAC form): PMID 19386527 — serum protein profile changes following GH/IGF-1 axis activation by CJC-1295 in normal adult subjects; a biomarker-discovery study, undertaken because IGF-1, IGFBP-3 and collagen peptides vary substantially in the population and are not reliably predictive of GH therapy's effects or of GH abuse.
Compound identification and the albumin mechanism: PMID 15817669 — CJC-1295 identified as a tetra-substituted hGRF(1-29) bearing an N-epsilon-3-maleimidopropionamide lysine at the C-terminus, bioconjugating to the free thiol at Cys34 of serum albumin; plasma presence beyond 72 hours in rats.
Why the backbone is substituted at all: PMID 8583376 — GRF(1-29)NH2 is degraded mainly by dipeptidyl peptidase IV to the inactive GRF(3-29)NH2; the D-Ala2-substituted analogue resists that cleavage.
Registry status: ClinicalTrials.gov lists a single study with CJC-1295 as an intervention, NCT00267527 (HIV patients with visceral obesity), status TERMINATED. No approved product exists in either form.
No-DAC form: no human efficacy or pharmacokinetic trial is indexed. Reported dosing figures for it are community heuristics, not trial-derived values.
Sold and discussed for research and educational use only. No long-term human safety data exists for either form.
Research timeline
Dated milestones taken from the primary records: the molecule's discovery, its first registered human study, the trials that shaped the evidence and the regulatory decisions. Each entry links to the record it comes from.
ConjuChem's researchers identify CJC-1295, a modified copy of the first 29 amino acids of growth-hormone-releasing hormone with a reactive group that binds it to albumin in the blood; in rats it was still present in plasma beyond 72 hours. This is the oldest record PubMed indexes under the name. PMID 15817669
ConjuChem starts a Phase 2 trial of CJC-1295 in people with HIV and abdominal (visceral) obesity, planned for 120 participants; the registry lists it as terminated in September 2006, gives no reason and posts no results. NCT00267527
Two randomised, placebo-controlled trials in healthy adults report that a single injection raised growth hormone for six days or more and IGF-1 for 9-11 days, with an estimated half-life of 5.8-8.1 days and no serious adverse reactions. PMID 16352683
A study of overnight blood sampling in healthy young men finds that growth hormone keeps its natural pulses a week after one injection of CJC-1295: the pulses are no larger or more frequent, but the level between them rises sharply. PMID 17018654
A Norwegian anti-doping laboratory reports a preparation seized by police and customs in 2009 that contained a 29-amino-acid peptide matching CJC-1295, and notes that it is prohibited under section S2 of the WADA list. PMID 21204297
FDA's Pharmacy Compounding Advisory Committee votes against adding any of five CJC-1295 forms, with and without DAC, to the pharmacy-compounding (503A) list: 0 in favour and 13 against for four forms, 1 in favour and 12 against for CJC-1295 acetate. FDA · PCAC minutes, Dec 4, 2024
FDA's page on compounding safety risks, as updated on this date, lists CJC-1295 among substances that had been in Category 2 and whose nominations were withdrawn, recording serious adverse events including increased heart rate and a systemic vasodilatory reaction. FDA · compounding safety risks, Apr 22, 2026
Records checked Oct 4, 2026
Claims at a glance
The claims most often made about this compound, each with the strongest kind of evidence we found for it. The grade says what was studied, not whether the claim is true; the line beside it says what that study showed.
Raises growth hormone and IGF-1 for daysHuman, randomised trial. Two placebo-controlled trials in healthy adults: growth hormone rose 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days. PMID 16352683
Lasts about a week in the bodyHuman, randomised trial. The same trials estimated a half-life of 5.8 to 8.1 days in healthy adults. PMID 16352683
Keeps the body's natural growth-hormone pulsesHuman, non-randomised. Overnight sampling in healthy men aged 20 to 40, before and one week after: pulse frequency and size unchanged, while baseline levels rose 7.5-fold. PMID 17018654
Burns fatAnimal studies only. Body composition was measured only in mice bred without their own growth-hormone-releasing hormone; no human study measured fat or weight. PMID 16822960
Builds muscle and strengthNo study found. Never measured in any species; the strength result often quoted comes from a rat study of ipamorelin given with a steroid, with no CJC-1295 in it. PMID 11735244
Improves sleepNo study found. Not measured: the one overnight human study sampled hormone levels every 20 minutes but recorded nothing about sleep. PMID 17018654
The reasoning behind each grade, study by study, is in this guide's Benefit & Outcome Review.
Grades checked Oct 5, 2026
A printable reference sheet with the compound's key facts, storage guidance and a vial record comes with All-Access Lifetime.
Half-life & pharmacokinetics
This is the field where the two forms are most often merged, so it is worth separating them by source.
The DAC form has a measured human half-life of 5.8-8.1 days (PMID 16352683), and the companion study describes the analogue as binding permanently to endogenous albumin after injection with a half-life of 8 days (PMID 17018654). These are real measurements in healthy adults. Critically, they are properties of the albumin conjugate. Albumin itself circulates for weeks, and a molecule covalently bonded to Cys34 inherits much of that persistence — which is precisely what the maleimide was put there to achieve.
The no-DAC form is routinely quoted at about 30 minutes. That figure is not a published human measurement of this peptide, and no dedicated pharmacokinetic study of the no-DAC peptide in humans is indexed. What can be sourced is the chemistry underneath it: unmodified GRF(1-29)NH2 is cleaved by dipeptidyl peptidase IV to the inactive GRF(3-29)NH2 and is short-lived in plasma, while the substituted backbone resists that specific cleavage (PMID 8583376). So the no-DAC peptide should outlast native GHRH(1-29) — the substitutions do something — but 'longer than a few minutes' is a direction, not a number, and the widely repeated half-hour figure has the status of an estimate that has been quoted long enough to look like data.
The practical reading: for the DAC form the half-life is one of the best-supported facts about the compound; for the no-DAC form it is one of the weakest, and the fact that both circulate under the same product name is the reason the distinction keeps collapsing.
Reported side effects & toxicology
In the human pharmacokinetic trials of the DAC form, no serious adverse reactions were reported, and doses of 30 or 60 mcg/kg were described as safe and relatively well tolerated (PMID 16352683). That is a genuine finding and it is also a narrow one: it covers small numbers of healthy volunteers over 28 and 49 days, with hormone concentrations as the endpoints.
Commonly reported effects across GHRH analogues generally include injection-site reactions, transient flushing or warmth, headache, water retention, and tingling or numbness in the hands consistent with fluid shifts. These are reported observations from the compound class, not trial-quantified rates for this molecule.
The substantive safety gap is duration and endpoint. Nothing in the human record addresses what sustained elevation of IGF-1 does over months or years, because no trial ran that long — and the multiple-dose arm's finding that IGF-1 stayed above baseline for up to 28 days after dosing stopped is exactly the kind of result that raises the question rather than answering it. Both forms are prohibited in sport under the WADA list, and neither is approved for any indication in any jurisdiction.
Storage & handling
Lyophilised vials are typically stored refrigerated; the powder is the stable state and the reconstituted solution is not.
After reconstitution with bacteriostatic water, storage is refrigerated. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is what makes multiple withdrawals from one vial possible; sterile water contains no preservative and does not.
Protect from light and avoid repeated freeze-thaw cycles, which are a routine cause of peptide degradation independent of the compound.
Label the vial with the date of reconstitution and the concentration in mcg/mL. The concentration is not recoverable from looking at the vial, and mixing up two vials reconstituted to different strengths is the most common source of a unit-math error.
References
Compiled from primary sources: the human pharmacokinetic and pharmacodynamic trials of CJC-1295 with DAC (PMID 16352683; PMID 17018654), the serum-biomarker study in normal adults (PMID 19386527), the compound-identification and albumin-bioconjugation paper (PMID 15817669), the dipeptidyl peptidase IV degradation work establishing why GRF(1-29) is substituted (PMID 8583376), and the ClinicalTrials.gov registry record NCT00267527. Presented for research and educational use only; not medical advice, and not a recommendation of any dose, route or schedule.
Evidence File
CJC-1295 with DAC: The Human Record, Read Line by Line
The free guide lists the human studies for CJC-1295 with DAC. This file goes back to the source documents and reads them the way a reviewer would: who was enrolled, how many independent cohorts there really are, which sentences are measurements and which are background summaries repeating someone else, and what the one registered trial record does and does not contain once every field is opened. It also carries a US federal regulatory entry naming this compound that the free page does not mention, a published third-party evidence grade, and a list of endpoints that no published human study has ever measured.
3 publications, at most 2 independent human cohorts
Half-life 5.8-8.1 days measured; the famous 8 days is a background line
1 registered trial: no results table, no linked publication, no stated reason
FDA names CJC-1295 in its nominated-but-withdrawn category-2 table
Three Publications, At Most Two Independent Cohorts
The Eight-Day Half-Life Is a Background Sentence, Not a Measurement
NCT00267527: Everything the Record Holds, and Everything It Does Not
Two Sentences in the Pulsatility Study That Change How It Reads
The Animal Record, and an Interval Result That Runs Backwards
A US Federal Safety Entry That Names CJC-1295
Tier B, and Two Safety Statements That Are Both True
The Endpoints That Have Never Been Measured
8 more sections in the Evidence File for CJC-1295
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for CJC-1295 for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Sourcing File
CJC-1295 with DAC: What a Certificate Has to Prove, and the Numbers That Prove It
Two different molecules are sold under the name CJC-1295, and on a certificate of analysis they are separated by one exactly known number. This file derives that number from the registered sequence, shows where two official databases disagree about this compound's own formula and which one to trust, identifies a mass value in a public record that looks like a protonated ion and is not, names the one US federal label document that does exist for this substance and what it actually is, works the salt and water arithmetic that decides how much peptide a labelled vial really holds, and reads a certificate line by line to say what each line establishes and what it leaves open.
279.122 Da is the entire difference between the DAC and no-DAC molecules
PubChem ExactMass 3646.0188 is the 13C peak, not [M+H]+ at 3646.0228
A 5 mg TFA-salt vial can hold about 4.0 mg of actual peptide
This molecule has no sulfur, so a +16 Met-oxide impurity is impossible
The Identity Numbers, and Where Two Official Databases Disagree
The Sequence, the Four Substitutions, and the Formula Recomputed
279.122 Daltons: The One Number That Separates the Two Products
The Mass Spectrometry Panel, and the Number That Is Not What It Looks Like
How Much Peptide Is Actually in a Five Milligram Vial
Failure Modes That Belong to This Molecule Specifically
A Certificate of Analysis, Read Line by Line
7 more sections in the Sourcing File for CJC-1295
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for CJC-1295 for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Benefit & Outcome Review
CJC-1295 with DAC: Eleven Marketed Claims, Graded Against the Evidence That Exists
The claims made for this compound are not a matter of opinion, and neither is the evidence behind each one. This file takes eleven claims in circulation, names where each of them came from, and grades them one at a time with human, animal and laboratory evidence kept strictly apart. It states what would have to exist for any of the ungraded claims to move, using an approved compound in the same class and the same patient population as the yardstick. It also traces the most-quoted strength figure in the market back to the experiment it appears to have come from, and sets out what the published record says about how individual people responded.
11 marketed claims graded; 3 supported in humans, all as hormone readings
Strength, sleep, skin and healing: never measured in any species
The quoted strength result traces to a rat study of ipamorelin and a steroid
No published study reports how many subjects responded, or by how much
Where the Claim List Came From, and How One of Them Was Manufactured
The Three Claims That Hold, and Exactly What They Hold As
Fat Loss and Lean Mass, and What It Took an Approved Compound to Earn the Same Claim
Sleep, Skin and Injury Healing: Three Claims, No Measurement
The Strength Figure That Belongs to a Different Experiment
From Half-Life to Dosing Interval: The Inference Nobody Has Tested
Safety: Two True Statements That Cover Different Ground
Who Responded, and by How Much: The Analysis That Was Never Published
8 more sections in the Benefit & Outcome Review for CJC-1295
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for CJC-1295 for $14 — or every compound in the library, plus the printable reference sheets, for $99.
Quick answers about guide scope, access, and educational use context.
What dose of CJC-1295 with DAC was used in the human studies?
30, 60 and 90 mcg/kg as single subcutaneous injections. The pharmacokinetic trial used ascending single doses and then two or three weekly or biweekly doses, and identified 30 and 60 mcg/kg as safe and relatively well tolerated (PMID 16352683); the pulsatility study used 60 or 90 mcg/kg (PMID 17018654). For a 70 kg adult those work out to roughly 2,100, 4,200 and 6,300 mcg per injection. This is a statement of what the trials administered, not a recommendation.
Is CJC-1295 with DAC the same as CJC-1295 without DAC?
No. They share the tetra-substituted GHRH(1-29) backbone, but the DAC version additionally carries an N-epsilon-3-maleimidopropionamide lysine at the C-terminus that reacts with the free thiol at cysteine-34 of serum albumin, covalently attaching the peptide to albumin in circulation (PMID 15817669). That attachment is the entire source of the multi-day half-life. The no-DAC version is the same molecule as Mod GRF 1-29.
What is the half-life of CJC-1295 with DAC?
5.8-8.1 days, measured in healthy adults (PMID 16352683); the companion human study describes it as approximately 8 days (PMID 17018654). The figure belongs to the albumin conjugate rather than to the GHRH backbone, which is why it does not transfer to the no-DAC form.
What is the half-life of CJC-1295 no DAC?
There is no published human measurement. The widely quoted 'about 30 minutes' is an estimate rather than a trial result — no dedicated pharmacokinetic study of the no-DAC peptide in humans is indexed. What is documented is the chemistry it rests on: native GRF(1-29)NH2 is cleaved by dipeptidyl peptidase IV to the inactive GRF(3-29)NH2, and the substituted backbone resists that cleavage (PMID 8583376). The peptide should therefore outlast native GHRH, but 'longer' is a direction, not a measured number.
How many clinical trials of CJC-1295 are there?
ClinicalTrials.gov lists one study with CJC-1295 as an intervention — NCT00267527, in HIV patients with visceral obesity — and its recorded status is TERMINATED. Three published human datasets exist, all on the DAC form and all Phase 1-scale pharmacology in healthy volunteers: the ascending-dose pharmacokinetic trials (PMID 16352683), the GH-pulsatility study (PMID 17018654), and a serum-biomarker study of GH/IGF-1 axis activation (PMID 19386527). None is an efficacy trial, and no CJC-1295 product has been approved anywhere.
Does CJC-1295 flatten natural GH pulsatility?
It was tested and it did not, at the doses studied. Healthy men were sampled every 20 minutes over a 12-hour overnight window before and one week after a single 60 or 90 mcg/kg injection; GH secretion increased with pulsatility preserved (PMID 17018654). This matters because pulsatile GH secretion is considered important for many of the hormone's physiological effects, so a long-acting analogue flattening the rhythm was the obvious theoretical objection.
Why is CJC-1295 substituted at all — what do the modifications do?
They defeat a specific enzyme. Native GRF(1-29)NH2 is degraded mainly by dipeptidyl peptidase IV, which cleaves after the second residue and leaves the inactive fragment GRF(3-29)NH2. A D-alanine at position 2 is not a substrate DPP-IV recognises, and the substituted analogue was shown to be markedly more stable than the native peptide (PMID 8583376). The substitutions extend survival in plasma; the DAC, when present, is what extends it to days.
What can a CJC-1295 certificate of analysis actually establish?
A COA typically reports identity by mass spectrometry and purity by HPLC for one batch. Mass spectrometry is the field that matters most for this compound, because the DAC and no-DAC forms differ by a defined added group and therefore by mass — an identity check distinguishes them where a purity percentage cannot. What a COA cannot establish: that the tested batch is the vial you received, that the peptide is sterile, or anything about the reconstitution water. Purity is also not potency; a high-purity result on the wrong molecule is still the wrong molecule.
Can community dosing figures for CJC-1295 be treated as clinical doses?
No, and the gap is large rather than marginal. The weekly amounts quoted for the DAC form sit below the smallest single injection either human trial gave. The commonly cited 'saturation dose' for the no-DAC form is a community heuristic with no published human dose-response study behind it. Quoting a trial half-life next to a community dose combines two incompatible sources.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
A certificate of analysis (COA) is a laboratory’s report on one sample of one batch. The single most useful thing to know about it is that purity and identity are two separate results that fail in different ways. A high purity figure says the sample was mostly one substance; it does not say that substance was CJC-1295. Identity — normally a mass-spectrometry result matching the expected molecular weight — is what establishes what the material actually is, and a certificate reporting purity alone has not answered that question.
Two further limits are worth holding onto. Mass per vial is its own test: a vial can be 99% pure and still contain less material than the label claims. And sterility, endotoxin, heavy metals and residual solvent screening are separately commissioned tests, usually priced individually — so a “third-party tested” badge asserts none of them unless the certificate names them. Check that the batch or lot number on the document matches the vial in front of you; an unmatched certificate describes someone else’s material.
Specific to CJC-1295
CJC-1295 exists as two different molecules — with DAC and without DAC (Mod GRF 1-29) — and they have different molecular weights. A certificate that reports only "CJC-1295" without stating which form was tested has not established which one is in the vial, and that is the one specification that changes everything downstream about the material.
Medibact does not test, endorse or resell peptides, and publishes no rating of any laboratory. How to read a peptide certificate of analysis walks through the document section by section, and what each COA field establishes covers the field-by-field detail and the laboratories that publish their methods.
You’ll need bacteriostatic water
The diluent for reconstituting CJC-1295
Reconstitution is volume arithmetic — it assumes a lyophilized vial is dissolved in bacteriostatic water, which is sterile water preserved with 0.9% benzyl alcohol. The preservative is what allows a vial to be entered more than once; plain sterile water carries none and is single-entry by design. Medibact supplies USP-grade Bacteriostatic Water for Injection in a 30 mL multi-dose vial, produced in an FDA-registered U.S. facility and shipped from the United States, for research use only. One 30 mL vial covers 30 reconstitutions at 1 mL each, 15 at 2 mL, or 10 at 3 mL — division only, not a dosing recommendation.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
